Thomas Steyer’s Abeona Therapeutics ABEO Stock Holding History

Thomas Steyer’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-80,000	Closed	-$6.54M	–	103
2019 Q4	$6.54M	Buy	+80,000	New	+$5.64M	0.04%	105

Other funds holding ABEO

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Thomas Steyer's ABEO Position: Q1 2020 in Review

Thomas Steyer sold out of Abeona Therapeutics (ABEO) in Q1 2020, closing a stake of 80,000 shares — an estimated $6.54M sold.

Thomas Steyer first reported a position in ABEO in Q4 2019 and held it in 1 quarter. The position peaked at $6.54M in Q4 2019. 80 funds tracked by Wall St. Rank hold ABEO as of Q1 2020.

Thomas Steyer reported no remaining Abeona Therapeutics position as of Q1 2020 after selling out during the quarter.
Thomas Steyer sold 80,000 Abeona Therapeutics shares in Q1 2020, an estimated $6.54M.
Thomas Steyer first reported a position in Abeona Therapeutics in Q4 2019 and held it in 1 quarter.
Thomas Steyer's Abeona Therapeutics position peaked at $6.54M in Q4 2019.
80 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.